Growth Funding

The company's liquidity position was strengthened by a successful fundraising of €48.2 million in March 2026, attracting top-tier US and European healthcare investors. This influx of capital positions Medincell for future growth initiatives. The "Shift to Growth" strategy is advancing, with the expected commercial launch of Olanzapine LAI by Teva in Q4 2026. The pipeline expansion continues, with several programs progressing towards clinical development.